President Bach Sells $4.4M Worth of Microsoft
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
12:39PM 10/27/09
Early Movers: Pump Up the Volume
Several small-cap stocks were poised to move on above-average volume during Monday's session.
08:29AM 10/26/09
Director Sells $20.8M Worth of Gap
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
09:13AM 09/08/09
Cabelas Director Buys $1.8M Worth
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
09:09AM 09/03/09
Hugoton Royalty Chair Buys $4M Worth
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
10:17AM 08/28/09
Linn Energy Chairman Sells $8.8M Worth
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
10:28AM 08/20/09
Insider Buys $5M Worth of Americredit
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
10:45AM 08/18/09
Biotech Earnings Preview: A Place to Hide?
Biotech stocks face challenges due to seasonality, raised expectations and the foreign exchange rate, but investors may turn to the sector in a defensive move.
03:17PM 10/13/08
Celgene Beats Targets, Guides In Line
The biotech company posts earnings that are 2 cents better than Wall Street expectations.
10:25AM 07/24/08
Biotech Earnings: Second-Quarter Preview
Here's what to look for when these seven big biotech companies report upcoming results for the second quarter.
10:23AM 07/11/08
Biotech-Stock Mailbag: Amgen, MiddleBrook
Examining Amgen's discount; updating MiddleBrook; valuing Seattle Genetics; and comparing SuperGen to Celgene.
07:59AM 07/04/08
Health Winners & Losers: Maxygen
Maxygen climbs on news of a deal with Bayer HealthCare.
04:16PM 07/02/08
Small-Cap Winners & Losers: SuperGen
The pharmaceutical company plummets after announcing a failed drug trial.
04:23PM 07/01/08
SuperGen Bust a Boon for Celgene (Update)
Dacogen's failed trial in myelodysplastic syndromes opens the door to greater market share for Celgene's Vidaza.
03:11PM 07/01/08
A Negative for SuperGen, a Plus for Celgene
Dacogen failed a late-stage trial in myelodysplastic syndromes, but that's good news for the fall launch of Celgene's Vidaza.
10:52AM 07/01/08



Connect with TheStreet